“Drugs companies publish only a fraction of their results and keep much of the information to themselves, but regulators want to ban the practice. If companies published all of their clinical trials data, independent scientists could reanalyse their results and check companies’ claims about the safety and efficacy of drugs. Under proposals being thrashed out in Europe, drugs companies would be compelled to release all of their data, including results that show drugs do not work or cause dangerous side-effects. The latest strategy shows how patient groups – many of which receive some or all of their funding from drugs companies – have been brought into the battle.”
Related posts:
Myanmar Stock Exchange Launch Moved Up To 2013 After Security Exchange Law Passed
China National Nuclear to Raise $2.6 Billion in IPO
Bloomberg outage causes financial havoc as UK forced to delay £3bn debt sale
Venezuela's gold reserves fall 24% in 18 months
Amazon launches online wine store
Obama Deploys US Troops to Iraq as Insurgents Gain Ground
Japan’s economic minister wants Nikkei to surge 17% to 13,000 by March
Internet giant Amazon hit by first strike in Germany
SEC blocks Chicago Stock Exchange sale over Chinese investor participation
ObamaCare's architects reap windfall as Washington lobbyists
Egypt's Tamarod protest movement
Jim Rogers: Gold Mining Stocks Face Two Major Headwinds
Der Spiegel Laments The Rapid Spread of Printable Pistols
ECB's Celebration of Its New $1.4 Billion Tower Is Spoiled by Protesters
Fitch expects 'Bond Bubble' carnage when rate cycle turns